Thursday witnessed an unprecedented surge in market enthusiasm as Candel Therapeutics, Inc. (NASDAQ: CADL) stunned investors with a monumental leap of nearly 280%, soaring from $1.68 to $6.40. Yet, the spectacle continued in the aftermarket trading hours, with CADL’s price rocketing further by a staggering 9%.
This whirlwind of activity underscores the intense fervor surrounding the company, evidenced by an extraordinary volume of over 142 million shares changing hands, a stark contrast to the typical daily average of a mere 80,000 shares.
Pancreatic Cancer Study Results
Fueling this meteoric rise is the revelation of profoundly positive outcomes from Candel Therapeutics’ groundbreaking pancreatic cancer study. Positioned as a leading biotechnology firm specializing in late-stage viral immunotherapies, the company’s latest triumph underscores its unwavering commitment to pioneering advancements in cancer treatment.
Unveiling updated interim survival data from its ongoing phase 2 trial of CAN-2409, an immunotherapy of considerable promise, in conjunction with valacyclovir and standard chemoradiation, Candel Therapeutics unveiled an array of compelling findings. Presented at the esteemed 2023 Society for Immunotherapy Annual Meeting, these results showcased:
- A striking median overall survival period of 28.8 months within the CAN-2409 cohort, a stark contrast to the 12.5 months observed in the control group.
- Encouraging survival rates of 71.4% and 47.6% at the 24 and 36-month milestones respectively among patients treated with CAN-2409.
- Of particular note, 4 out of 7 patients administered CAN-2409 were still alive at the data cut-off, with two surpassing the remarkable milestone of 50 months since enrollment.
- Significantly, Candel Therapeutics’ immunotherapy elicited a robust activation of the immune response, evidenced by consistent findings in both blood and resected tumors.
Conclusion
Candel Therapeutics’ triumphant strides represent a significant breakthrough in the relentless battle against pancreatic cancer. The company’s steadfast dedication to pushing the boundaries of medical science not only ignites hope for future patients but also yields substantial value for CADL shareholders.
Pioneering the frontier as the first to unveil such promising data, Candel Therapeutics establishes a formidable precedent for the transformative potential of immunotherapy in cancer treatment. With continued momentum and a promising safety profile, CADL stands poised to redefine the landscape of oncological therapeutics, embarking on a trajectory of profound impact and innovation.
Leave a Reply